Literature DB >> 15570291

p-Iodophenol-enhanced luminol chemiluminescent assay applied to discrimination between acute lymphoblastic and minimally differentiated acute myeloid (FAB-M0) or acute megakaryoblastic (FAB-M7) leukemias.

Miriane da Costa1, Valdecir Farias Ximenes, Iguatemy Lourenço Brunetti, Roberto Passetto Falcão, Luiz Marcos da Fonseca.   

Abstract

INTRODUCTION: In this report, we propose the application of the p-iodophenol-enhanced luminol chemiluminescent technique to the determination of peroxidase (myeloperoxidase and/or platelet peroxidase) activity in blasts of minimally differentiated acute myeloblastic leukemia (AML-M0) and acute megakaryoblastic leukemia (AML-M7).
METHODS: The frozen blast cells from 29 patients were thawed and submitted to the optimized protocol.
RESULTS: All cases of AML-M7 and AML-M I exhibited integrated light emission greater than 73(10(2) mV x s), which was the arbitrary cutoff point set for the discrimination between AML and acute lymphoblastic leukemia (ALL) (mean + 3 x s.d. of ALL samples, n = 10). In addition, five out of seven cases of AML-MO showed results above the cutoff point.
CONCLUSION: This highly sensitive enhanced chemiluminescent technique may be applied to discriminate between ALL and AML-M7 or AML-MI cases, and most AML-M0 cases. It is very simple, cheap and easy to perform compared to other procedures used to measure MPO activity in AML-leukemias including AML-M7 and AML-M0.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15570291     DOI: 10.1038/sj.thj.6200562

Source DB:  PubMed          Journal:  Hematol J        ISSN: 1466-4860


  1 in total

1.  Chemiluminescent determination of leukocyte alkaline phosphatase: an advantageous alternative to the cytochemical assay.

Authors:  Marília P P Kanegae; Valdecir F Ximenes; Roberto P Falcão; Virgílio A R Colturato; Ederson R de Mattos; Iguatemy L Brunetti; Luiz Marcos da Fonseca
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.